Improving antidepressant drugs: Update on recently patented compounds

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 6, 2009, Pages 827-845

  Rozas, Isabel ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

2 adrenoceptor antagonist; 5 HT antagonist; Antidepressants; Fluoxetine; Glycinergic system; Melatonin; Mirtazapine; Multi target drugs; Schizophrenia; SNRI; SSRI

Indexed keywords

AGOMELATINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; BENZODIOXAN DERIVATIVE; CANNABINOID 1 RECEPTOR ANTAGONIST; DESIPRAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FLUOXETINE; HALOPERIDOL; IDAZOXAN; IMIPRAMINE; ISOXAZOLINE DERIVATIVE; MELATONIN; MIRTAZAPINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; MU OPIATE RECEPTOR AGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; PAROXETINE; PHOSPHODIESTERASE IV INHIBITOR; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VENLAFAXINE;

ADJUVANT THERAPY; ANXIETY DISORDER; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; DATA BASE; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EUROPE; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PATENT; PATHOPHYSIOLOGY; POLYPHARMACY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN CHEMISTRY; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; HUMANS; NOREPINEPHRINE; PATENTS AS TOPIC; SCHIZOPHRENIA; SEROTONIN;

EID: 67649337310     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902932934     Document Type: Review

References (191)

1. Available from: http://www.who.int/mental-health/management/depression/ definition/en/
2. Mental Health Global Action Programme. Close the gap, dare to care. Geneva: World Health Organization; 2002
3. Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:435-451 (Pubitemid 38490755)
4. Frazer A. Antidepressants. J Clin Psychiatr 1997;58:9-25
5. Millan MJ. The role of monoamines in the actions of established and «novel» antidepressant agents: a critical review. Eur J Pharmacol 2004;500:371-384 (Pubitemid 39304021)
6. Invernizzi RW, Garattini S. Role of presynaptic α2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuro Psychopharmacol Biol Psychiatry 2004;28:819-827 •• This review reports the multi-target strategies to improve the treatement of depression from the neuronal substrates to the development of drugs. (Pubitemid 39195273)
7. Butler SG, Meegan MJ. Recent development in the design of anti-depressive therapies: targeting the serotonin transporter. Curr Med Chem 2008;15:1737-1761
8. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137-151 •• This review gives an excellent overview of the problems on the development of non-monoamine-based antidepressants, and of the most promising current strategies. (Pubitemid 43151600)
9. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
10. Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77
11. Rasmussen K. Creating more effective antidepressants: clues from the clinic. Drug Discov Today 2006;11:623-631 (Pubitemid 43912496)
12. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004;29:126-133 (Pubitemid 38570217)
13. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augementation strategies. J Clin Psychiatry 1998;59(Suppl 5):60-63 (Pubitemid 28249108)
14. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997;12(Suppl 3):S7-14 (Pubitemid 27414585)
15. Schmidt HD, Banasr M, Duman RS. Future antidepressant targets: neurotrophic factors and related signaling cascades. Drug Discov Today Ther Strateg 2008;5:151-156
16. EPO searching engine. Available from: http://ep.espacenet.com/
17. Nencetti S, Lapucci A. 4-Arylpiperidine derivatives and use thereof for preparing a medicament for the treatment of CNS disorders. WO2006106432; 2006
18. Gerdes JM, Bolstad DB. Enantiomers of 2′-fluoralkyl-6- nitroquipazine as Serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics. WO2007127262; 2007
19. Shanghai INST. Pharm. Industry. Aralkyl-alcohol piperazine derivatives adn their uses as antgyepressant. US2005267121; 2005
20. Gruenenthal GMBH. New substituted 1-oxo-3,8-diazospiro(4.5)-decan-2-one compounds are 5-hydroxy tryptamine uptake receptor inhibitors, useful to treat and/or prevent e.g. pain, migraine, chronic paroxysomal hemicrania, depression and asthma. DE102005030051; 2006
21. Lundbeck & Co As. 2-(1H-indolylsulfanyl)-benzyl amine derivative. P2007277254; 2007
22. Natco Pharma Ltd. 3-Aryloxy 3-Substituted Propanamines. WO2008081477; 2008
23. Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597 (Pubitemid 27229140)
24. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxan methylamines. KR20050061470; 2005
25. Wyeth Corp. Antidepressant piperidine derivatives of heterocycle-fused benzodioxans. KR20050042192; 2005
26. Wyeth Corp. Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans. KR20050042187; 2005
27. Wyeth Corp. Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines. KR20050042176; 2005
28. Wyeth Corp. Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans. MXPA05002743; 2005
29. Wyeth Corp. Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan. MXPA05002740; 2005
30. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-dioxa-3-azacyclopenta[a]naphtalene. MXPA03009829; 2005
31. Wyeth Corp. Antidepressant (SSRI) azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1, 3-diazacyclopenta[a]naphtalene. MXPA03009828; 2005
32. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f ]quinaxoline. MXPA03009826; 2005
33. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans. MXPA03009825; 2005
34. Wyeth Corp. Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxans. EP1537103; 2005
35. Wyeth Corp. Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole. WO02088146; 2005
36. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene. US2005228010; 2005
37. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene. US2005004209; 2005
38. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans. ZA200502043; 2006
39. Wyeth Corp. Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans. ZA200502047; 2006
40. Wyeth Corp. Antidepressant piperidine derivatives of heterocycle-fused benzodioxans. ZA200502042; 2006
41. Wyeth Corp. Antidepressant indolealkyl derivatives of heterocyclefused benzodioxan methylamines. ZA200502040; 2006
42. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans. US2006293301; 2006
43. Wyeth Corp. Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans. US2006276481; 2006
44. Wyeth Corp. Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans. NZ539253; 2006
45. Wyeth Corp. Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan. US2006160881; 2006
46. Wyeth Corp. Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans. US2007004702; 2007
47. Wyeth Corp. Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans. WO2008150848; 2008
48. Wyeth Corp. Antidepressant indolealkyl derivatives of heterocyclefused benzodioxan methylamines. CN101143867; 2008
49. Wyeth Corp. Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans. CN101239953; 2008
50. Wyeth Corp. Antidepressant piperidine derivatives of heterocycle-fused benzodioxans. CN101230066; 2008
51. Cheetham SC, Viggers JA, Slater NA, et al. [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology 1993;32:737-743 (Pubitemid 23227658)
52. Hall MD, El Mestikawy S, Emerit MB, et al. [3H]8-Hydroxy-2-(di-n- propylamino) tetraline binding to pre- and postsynaptic 5-Hydroxytryptamine sites in various regions of the rat brain. J Neurochem 1985;44:1685-1696 (Pubitemid 15000270)
53. Merck Patent GmbH. Derivatives of pyridinalkyl-amonoalkyl-1h-indole inhibiting receptors 5-ht and recapture of serotonin which can be used as antidepressant and anxiolitic. KR20050085038; 2005
54. Merck Patent GmbH. Benzofuran oxyethylamines serving as antidepressant drugs and anxiolytic drugs. PL377618; 2006
55. Merck Patent GmbH. Indole derivatives as serotonin reuptake inhibitors. MXPA05013538; 2006
56. UCB SA. 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments. MXPA05003290; 2005
57. UCB SA. Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases. EP1693061; 2006
58. Ge JA, Barnes NM. 5-HT4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. Br J Pharmacol 1996;117:1475-1480 (Pubitemid 3040750)
59. Lucas G, Debonnel G. 5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. Eur J Neurosci 2002;16:817-822 (Pubitemid 35463573)
60. Lucas G, Compan V, Charnay Y, et al. Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biol Psychiatry 2005;57:918-925 (Pubitemid 40488361)
61. Lucas G, Rymar VV, Du J, et al. Serotonin(4) (5-HT4) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007;55:712-725
62. Debonnel G, Lucas G. Stimulators of 5-ht4 receptors and uses thereof. WO2006029520; 2006
63. Heinrich T, Bottcher H. Indole derivatives as serotonin reuptake inhibitors. US2006160824; 2006
64. Pinney KG, Miranda MG. Serotonin reuptake inhibitors. WO2005094896; 2005
65. Pinney KG, Miranda MG. Serotonin reuptake inhibitors. US2008132514; 2008
66. Janssen Pharmaceutica. C-substituted tricyclic isoxazoline derivatives and their use as anti-depressants. US2005256119; 2005
67. Alpha 2 Pharmaceutical. Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor. WO2006083204; 2006
68. Alpha 2 Pharmaceutical. Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor. US2008269306; 2008
69. Soares JC, Innis RB. Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 1999;46:600-615 (Pubitemid 29401858)
70. Lilly Co. Eli. Combination therapy for treatment of psychoses. EP830864; 1997
71. Feenstra R, Ronken E, Koopman T, et al. SLV308. antiparkinsonian, antidepressant, anxiolytic, dopamine D2 partial agonist, 5-HT1A agonist. Drugs Future 2001;26:128-132 (Pubitemid 32367072)
72. Solvay Pharmaceuticals BV. New phenylpiperazines useful for treating central nervous system disorders caused by dopaminergic or serotonergic systems. NZ523135; 2005
73. Solvay Pharmaceuticals BV. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. US2006122189, US2006122190, US2006247256; 2006
74. Solvay Pharmaceuticals BV. Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. US2006122175, CA2587940; 2006
75. Solvay Pharmaceuticals BV. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptakesites. US2006122177. CA2587928; 2006
76. Solvay Pharmaceuticals BV. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. US2006122206, CA2587936; 2006
77. Solvay Pharmaceuticals BV. Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. US2006122247; 2006
78. Solvay Pharmaceuticals BV. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. EP1824479, EP1824480, EP1827426, EP1828161, MX2007006818; 2007
79. Solvay Pharmaceuticals BV. Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. EP1824486, MX2007006758; 2007
80. Solvay Pharmaceuticals BV. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. EP1828168, MX2007006757; 2007
81. Solvay Pharmaceuticals BV. 8-{4-[3-(5-fluoro-1H-indol-3-YLl)-propyl]- piperazin-1-YL)-2-methyl-4H-benzo[1,4]. oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site. AU2002250983; 2006
82. Solvay Pharmaceuticals BV. Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. SI1827427; 2008
83. Solvay Pharmaceuticals BV. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites. MX2007006756; 2007
84. Solvay Pharmaceuticals BV. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. HR20090015; 2009
85. Squibb Bristol Myers Co. Antipsychotic heterocycle compounds. EP1598068; 2005
86. Sindrup J. Anesthesia: Biological foundations. In: Yaksh TL, Lynch C, Zapol W, et al. Philadelphia: Lippincott-Raven; 1997
87. Gruenenthal GmbH. C-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorder. US2006258741; 2006
88. Maggi CA. The troubled story of tachykinins and neurokinins. Trends Pharmacol Sci 2000;21:173-175 (Pubitemid 30243198)
89. Ryckmans T, Balançon L, Berton O, et al. First dual NK1 antagonists serotonin reuptake inhibitors: synthesis and SAR of a new class off potential antidepressants. Bioorg Med Chem Lett 2002;12:261-264 (Pubitemid 34037980)
90. Servier Lab. Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists. EP1710240; 2006
91. Sanofi Aventis. Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them. EP1707564; 2006
92. Edmonds-Alt X, Vilain P, Goulaouic P, et al. A potent and selective non-peptide antagonist of the neurokinin a (NH2) receptor. Life Sci 1992;50:PL101-6
93. Sanofi Aventis. Composition useful to treat e.g. anxiety disorder comprises (S)-(-)-N-(4-(4-acetamido-4-phenyl- 1-piperidyl)-2-(3, 4-dichlorophenyl) butyl)-N-methylbenzamide, (+/-)-N-methyl-3-phenyl-3-(4- (trifluoromethyl)phenoxy)-propan- 1-amine. FR2904221; 2008
94. Padgett LW. Recent developments in cannabinoid ligands. Life Sci 2005;77:1767-1798 (Pubitemid 41078745)
95. Muccioli GG, Lambert DM. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr Med Chem 2005;12:1361-1394 (Pubitemid 40872582)
96. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005;48:5059-5087 (Pubitemid 41113892)
97. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005;81:331-342 (Pubitemid 40807131)
98. Solvay Pharmaceuticals BV. Compounds with a combination of cannabinoid cb1 antagonism and serotonin reuptake inhibition. US2008214559, WO2008084057; 2008
99. Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997;36:419-428 (Pubitemid 27272086)
100. SmithKline Beecham PLC, Jones BJ, Routledge C. Composition containing 5-HT1A and 5-HTID antagonists. WO9531988; 1995
101. Maura G. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate and inhibition of cyclic GMP production in rat cerebellum in vitro. J Neurochem 1996;66:203-209 (Pubitemid 3015803)
102. Pfizer Prod., Inc. 5HT1 antagonists for antidepressant therapy. OA11742; 2005
103. Merck Patent GmbH. New 3-oxo-1-propenyl azo compounds useful as 5-HT receptor antagonists e.g. for treating psychoses, neurological disorders, amyotrophic lateral sclerosis and eating disorders. DE10360151; 2005
104. Merck Patent GmbH. New quinolonyl- or benzopyranonyl-substituted indole derivatives are 5HT(1A)- and/or 5HT(1D)-agonists useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents. DE10353657; 2005
105. Esteve Labor Dr. New tetrahydroisoquinoline substituted sulfonamide compounds useful as 5-HT7 receptor antagonist in the treatment of e.g. central nervous system disorders. ES2257168; 2006
106. Esteve Labor Dr. New dihydro-1H-isoquinoline compounds are 5-hydroxytryptamine-7 inhibitors useful for the treatment of e.g. sleep disorder, shift worker syndrome, depression, migraine, anxiety, psychosis, schizophrenia and pain. ES2257167; 2006
107. Terrón JA. The 5HT7 receptor: a target for novel therapeutic avenues? IDrugs 1998;1:302-310
108. Lovenberg TW, Baron BM, de Lecea L, et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of circadian rhythms. Neuron 1993;11:449-458 (Pubitemid 23287072)
109. Esteve Labor Dr. New indene derivatives useful for treating e.g. obesity, bulimia, anorexia, cachexia, diabetes, anxiety, panic attacks, depression and bipolar disorders. ES2274725; 2007
110. Yoshioka M, Matsumoto M, Togashi H, et al. Central distribution and function of 5-HT(6) receptor subtype in the rat brain. Ann NY Acad Sci 1998;861:244
111. Bourson A, Boess FG, Bos M, et al. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol 1998;125:1562-1566 (Pubitemid 28548569)
112. Rogers DC, Robinson TL, Quilter CA, et al. Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. Br J Pharmacol Suppl S 1999;127:22P
113. Branchek TA, Blackburn TP. 5-HT6 receptors as emerging targets for drug discovery. Ann Rev Pharmacol Toxicol 2000;40:319-334 (Pubitemid 30340685)
114. Routledge C, Bromidge SM, Moss SF, et al. Characterization of SB-271046: A potent, selective and orally active 5-HT6 receptor antagonist. Br J Pharmacol 2000;130:1606-1612 (Pubitemid 30611938)
115. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-1410 (Pubitemid 24100360)
116. Glatt CE, Snowman AM, Sibley DR, et al. Clozapine - selective labeling of sites resembling 5ht(6) serotonin receptors may reflect psychoactive profile. Mol Med 1995;1:398-406
117. Monsma FJ, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high-affinity for tricyclic psychotropic-drugs. Mol Pharmacol 1993;43:320-327 (Pubitemid 23081986)
118. Shinkai T, Ohmori O, Kojima H, et al. et al. Association study of the 5-HT6 receptor gene in schizophrenia. Am J Med Genet 1999;88:120-122 (Pubitemid 29156446)
119. Egis Gyogyszergyar Nyilvanosan. Pyridine derivatives of alkyloxindoles as 5-HT7 receptor active agents. HU0500462; 2007
120. Egis Gyogyszergyar Nyilvanosan. Pyperazine derivatives of alkyl-oxindoles. HU0500461; 2007
121. Egis Gyogyszergyar Nyilvanosan. Pyridine derivatives of dialkyl-oxindoles. HU0500463; 2007
122. Egis Gyogyszergyar Nyilvanosan. Piperazine derivatives of dialkyl-oxindoles. HU0500464; 2007
123. Fourtillan SNC. New 1-hydroxy- 3-oxo-propen-1-yl-hexahydro-pyrroloindole compounds are 5-hydroxy tryptamine-2 receptor antagonists useful to treat e.g. depression, anxiety, Parkinson's disease, Alzheimer's diseases, cancer, skin diseases and anxiety. FR2912747; 2008
124. Fourtillan SNC. New 3H,11Hoxazolo(3′,4′:1,2)pyrido(3,4-b) indole derivatives are 5-hydroxytryptamine-2 receptor activators useful e.g. to treat insomnia, jet lag, anxiety, depression and Alzheimers. FR2908767; 2008
125. Callado LF, Meana JJ, Grijalba B, et al. Selective increase of alpha2a-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem 1998;70:1114-1123 (Pubitemid 28113645)
126. Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ, et al. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: Selective supersensitivity of alpha2A-adrenoceptors. Mol Psychiatry 2002;7:755-767 •• This article presents evidence of the imvolvement of alpha2-adrenoceptors in depression. (Pubitemid 34984953)
127. Mateo Y, Fernandez-Pastor B, Meana JJ. Acute and chronic effects of desipramine and clorgyline on alpha2-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol 2001;133:1362-1370 (Pubitemid 32783498)
128. Fernandez-Pastor B, Meana JJ. In vivo tonic modulation of the noradrenaline release in the rat cortex by locus coeruleus somatodendritic alpha2-adrenoceptors. Eur J Pharmacol 2002;442:225-229
129. Devoto P, Flore G, Pani L, Gessa GL. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry 2001;6:657-664 (Pubitemid 33020584)
130. Mateo Y, Pineda J, Meana JJ. Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J Neurochem 1998;71:790-798 (Pubitemid 28480428)
131. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009;43:215-229
132. Rozas I, Rodriguez F, et al. Guanidine based Compounds. EP2008068199; 2008
133. Rozas I, Rodriguez F, et al. α2-Adrenoceptor Ligands. UK08234205; 2008
134. Van Der Burg WJ. Psychofarmaceutical Preparation. WO2006006858; 2006
135. Gmeiner P, Huebner H. New N-substituted 1-benzyl-1H-(1,2,3)-triazole-4- carboxamides, are dopamine and alpha-1 adrenergic receptor ligands useful for treating diseases of the urinary tract, vascular system or CNS. DE102004039065; 2006
136. Millan MJ, Bervoets K, Rivet JM, et al. Multiple alpha-2-adrenergic receptor subtypes .2. Evidence for a role of rat r(alpha-2a), adrenergic-receptors in the control of nociception, motor behavior and hippocampal synthesis of nor adrenaline. J Pharmacol Exp Ther 1994;270:958-972 (Pubitemid 24315208)
137. Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha(2)-adrenergic and serotonin(2C) receptors: a comparison with citalopram. Eur J Neurosci 2000;12:1079-1095
138. Gobert A, Di Cara B, Cistarelli L, et al. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha(2A)-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther 2003;305:338-346 (Pubitemid 36373869)
139. Kennett GA, Wood MD, Bright F, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997;36:609-620 (Pubitemid 27272106)
140. Servier Lab. Benzoindoline derivatives with adrenergic activity. EP1516871; 2005
141. Kinney GG, Sur C. Glycine site modulators and glycine transporter-1 inhibitors as novel therapeutic targets for the treatment of schizophrenia. Curr Neuropharmacol 2005;3:35-43 (Pubitemid 40246717)
142. Tech Egon. Combating stress states or nervous system or metabolic disorders, using glycine as neurotransmission modulator showing antistress, stress protective, nootropic and toxin binding actions. DE102005027905; 2005
143. Sanofi Aventis. New N-heterocyclylmethyl benzamide derivatives useful as glycine transporter inhibitors for e.g. treating dementia-associated behavioral problems, psychoses, anxiety, depression and alcohol abuse. FR2861076; 2005
144. Sanofi Aventis. Use of tricyclic compounds as glycine transport inhibitors. CN1882587; 2006
145. Swanson CJ, Bures M, Johnson MP, et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev Drug Discov 2005;4:131-144 (Pubitemid 40277494)
146. Nazakato A, Chaki S. 6-Fluorobicyclo[3.1.0]hexane derivatives. US2005119345; 2005
147. Servier Lab. Fluorinated benzothiadiazine derivatives and their use as AMPA receptor modulators. EP1557412; 2005
148. Servier Lab. Benzothiazine and benzothiadiazine derivatives, process for their preparation and phamaceutical compositions containing them. EP1669072; 2006
149. Servier Lab. Benzothiadiazine derivatives, method for preparing them and pharmaceutical compositions containing them. EP1655030; 2006
150. Servier Lab. Benzothiadiazine derivatives, process of preparation thereof and pharmaceutical compositions containing them. EP1655299; 2006
151. Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann NY Acad Sci 2003;1003:292-308 (Pubitemid 38083063)
152. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 2003;1003:250-272 (Pubitemid 38083061)
153. Gozin M, Weiner HL. Novel neuroprotective compounds and uses thereof. WO2006077597; 2006
154. Hermann HL. Use of S-(+)-ketamine for treating depression, which is therapy-refractive depression, preferably depressive episode, relapsing disorder and bipolar affective disorder. DE102007009888; 2008
155. Hatt H, Kragler A. Use of 1,3-dioxane derivatives to enhance the activity of gamma-aminobutyric acid (GABA) on GABA-A receptors. DE102007010077; 2008
156. Sanol Arznei Schwarz GmbH. Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders. EP1733727; 2006
157. Bioproject Soc Civ Ile. New arylpiperazine derivatives, useful to prevent and/or treat neuropsychiatric disorders e.g. disorders of drug dependence, sexual disorders and motor disturbance, are dopamine D3 receptor ligands. FR2878524; 2006
158. Bioproject Soc Civ Ile. Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor. EP1659112; 2006
159. Caldarone BJ, Harrist A, Cleary MA, et al. High affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry 2004;56:657-664 (Pubitemid 39446847)
160. Binder Eva Dkfm. New enantiomerically pure hexahydro-pyrrolo-cyclopenta- pyridine derivatives, useful as central nicotine receptor subtype agonists for e.g. treating Alzheimer's or Parkinson's disease, anxiety and depression. AT414305; 2006
161. Gruenenthal GmbH. New spiro-isoxazole-cycloalkane compounds, useful as vanilloid receptor 1 ligands for treating e.g. pain, depression and neurodegeneration. DE102005044814; 2006
162. Abbott GmbH & Co. KG. New substituted oxindole derivatives are vasopressin receptor binders useful to treat e.g. diabetes insipidus, enuresis nocturna, incontinence, hypertonia, heart failure, myocardial infarction, coronary spasm and renal disorders. DE102005015957; 2006
163. Abbott GmbH & Co. KG. New substituted oxindole derivatives are vasopressin receptor binders useful to treat e.g. diabetes insipidus, enuresis nocturna, incontinence, hypertonia, heart failure, myocardial infarction, coronary spasm and renal disorders. DE102005014628; 2006
164. Esteve Labor. Dr. New fused pyrazole derivatives, useful for treatment of psychosis and pain, are sigma receptor inhibitors. ES2251317; 2006
165. Sanofi Aventis Deutschland. Substituted 2 amino imidazoles, method for their manufacture and their use as a drug or diagnostic and drug containing them. EP1857445; 2007
166. Barden N, Shink E, Labbe M, et al. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:908-916 • This article gives evidence of the antidepressant activity of agomelatine, a new drug that act through different mechanisms.
167. Lucini V, Spadoni G. Novel melatonin ligands having antidepressant activity as well as sleep inducing properties. CA2636601; 2007
168. Gobbi G, Mor M. Novel elatonin ligands having antidepressant activity as well as sleep inducing properties. EP1973868; 2008
169. Servier Lab. New 3-acylaminoethyl-3-phenylthio-benzothiophene derivatives, are melatonin receptor ligands useful e.g. for treating sleeping disorders, anxiety, depression, jet lag or appetite disorders. FR2857011; 2005
170. Servier Lab. New indole derivatives are melatonin receptor binders useful to treat e.g. sleep disturbance, stress, anxiety, depression, cardiovascular diseases, digestive system disorders, schizophrenia, panic attack, obesity and insomnia. FR2907452; 2008
171. Servier Lab. New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them. EP1873140; 2008
172. Servier Lab. Use of agomelatin in the manufacture of a medicament for the treatment of bipolar disorders. EP1714647; 2006
173. Servier Lab. Use of agomelatine to obtain a medication aimed at treating generalised anxiety disorder. EP1842535; 2007
174. Servier Lab. Use of agomelatine to obtain a drug to treat Smith Magenis syndrome, major depression, seasonal depression, sleep disorder, cardiovascular disease, digestive system disorder, insomnia, shiftlag, appetite disorders and obesity. FR2908995; 2008
175. Chaki S, Okuyama S. Involvement of melanocortin-4 receptor in anxiety and depression. Peptides 2005;26:1952-1964 (Pubitemid 41354554)
176. Poitout L, Brault V. New 1,2,6-trisubstituted benzimidazole derivatives and imidazo-pyridine analogs, are melanocortin receptor ligands useful for treating e.g. obesity, cachexia, anxiety, depression or neuropathic pain. FR2862971; 2005
177. Chaki S, Oshida Y, Ogawa S, et al. MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacol Biochem Behav 2005;82:621-626 (Pubitemid 43184037)
178. Takeda Pharmaceutical. Antidepressant. PL371366; 2005
179. Takeda Pharmaceutical. Antidepressant. US2006241168; 2006
180. Bombardelli E, Morazzoni P. Use of hyperforin derivatives as an antidepressant agent. EP1607099; 2005
181. Boehringer Ingelheim Pharma. New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis. DE102004025552; 2005
182. Lodola A, Mor M, Rivara S, et al. Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modeling. Chem Commun 2008;214-216 (Pubitemid 350294105)
183. Sanofi Synthelabo. New 1-alkyl-(homo) piperazine-4-carboxylate ester derivatives, are fatty acid amidohydrolase inhibitors useful e.g. for treating pain, cancer or neurodegenerative, cardiovascular, inflammatory or allergic disease. FR2866888; 2005
184. Sanofi Synthelabo. Derivatives of arylalkylcarbamates, process for their preparation and therapeutic application thereof. EP1972616; 2008
185. Halene TB, Siegel SJ. PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia? Drug Discov Today 2007;12:870-878
186. Boehringer Ingelheim Pharma. New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease. DE102005023207; 2006
187. Boehringer Ingelheim Pharma. New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease. DE102005019718; 2006
188. Boehringer Ingelheim Pharma. New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease. DE102005035575; 2007
189. Boehringer Ingelheim Pharma. New substituted pteridine compounds, useful as phosphodiesterase 4 inhibitors for treating e.g. inflammatory diseases, cancer, asthma, ulcerative colitis, depression and schizophrenia. DE102004057645; 2006;
190. Servier Lab. New triazabenzo(a) naphtho(2,1,8-cde)azulene derivatives useful as tyrosine hydroxylase inducers, e.g. for treating depression or anxiety. FR2911141; 2008
191. Medtrack. Available from: http://www.medtrack.com/research/default.asp, Life Science Analytics, Inc